Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
Completed
Tinea Pharmaceuticals
Phase 2
2009-03-01
To examine the safety and optimal duration of Luliconazole Cream 1% treatments for 14 days or
28 days to achieve "complete clearance" at 2 weeks post treatment.
Open-Label Pharmacokinetics (PK)/Safety Study of Luliconazole Solution, 10% in Distal Subungual Onychomycosis
Completed
Topica Pharmaceuticals
Phase 1/Phase 2
2010-12-01
To determine the safety, tolerability, systemic exposure and pharmacokinetics of luliconazole
after repeat daily topical application of Luliconazole Solution, 10% in a maximal use setting
in adults with distal subungual onychomycosis of the toenails.
Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis
Completed
Topica Pharmaceuticals
Phase 2/Phase 3
2012-05-01
The purpose of this study is to determine the safety and efficacy of a topical antifungal
formulation, Luliconazole Solution, 10%, in the treatment of adults with onychomycosis of the
toenails.
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
Completed
Bausch Health Americas, Inc.
Phase 4
2015-02-03
This is an open-label, maximal use study to evaluate whether luliconazole in plasma acts as
an inhibitor of cytochrome P2C19 (CYP2C19) as measured by circulating levels of omeprazole
before and after treatment with a maximum dose of luliconazole cream 1% in participants with
moderate to severe tinea pedis and tinea cruris.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
